{"nct_id":"NCT00696072","title":"Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic","status":"COMPLETED","status_verified_date":"2016-05","start_date":"2008-08","start_date_type":null,"primary_completion_date":"2014-06","primary_completion_date_type":"ACTUAL","completion_date":"2014-06","completion_date_type":"ACTUAL","phases":["PHASE2"],"tickers":["BMY"]}